Kbc Group Nv Pacira Bio Sciences, Inc. Transaction History

Kbc Group Nv

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	SELL	$26.32 - $34.31 $58,588 - $76,374	-2,226 Reduced 60.74%	1,439 $49,000
Q3 2023 Feb 15, 2024	SELL	$30.68 - $40.09 $68,293 - $89,240	-2,226 Reduced 60.74%	1,439 $44,000
Q2 2023 Feb 15, 2024	SELL	$36.12 - $47.5 $6,754 - $8,882	-187 Reduced 4.85%	3,665 $147,000
Q2 2023 Jul 28, 2023	SELL	$36.12 - $47.5 $6,754 - $8,882	-187 Reduced 4.85%	3,665 $147,000
Q3 2022 Feb 15, 2024	BUY	$51.24 - $58.89 $123,642 - $142,101	2,413 Added 167.69%	3,852 $205,000
Q2 2022 Feb 14, 2024	BUY	$51.49 - $81.64 $115,080 - $182,465	2,235 Added 138.22%	3,852 $225,000
Q2 2022 Jul 26, 2022	BUY	$51.49 - $81.64 $115,080 - $182,465	2,235 Added 138.22%	3,852 $225,000
Q4 2021 Feb 14, 2024	BUY	$47.97 - $62.21 $8,538 - $11,073	178 Added 12.37%	1,617 $97,000
Q3 2020 Oct 28, 2020	BUY	$51.97 - $63.0 $84,035 - $101,871	1,617 New	1,617 $97,000

263

50.4M

429K

391K

Ticker PCRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 45,824,200
Market Cap $892M
Description
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...

Get notified when there are updates to the investment portfolio of Kbc Group Nv, based on Form 13F filings with the SEC.

Stay updated on Kbc Group Nv with notifications on news.